Dr. Thomas Pisansky, Professor of Radiation Oncology, Mayo Clinic
Stations, the following is a news announcement. Suggested lead in 3, 2, 1…
More than 11,000 of the world’s top cancer doctors and scientists gathered at the 55th annual meeting of the American Society for Radiation Oncology (ASTRO) in Atlanta. This year’s theme of the four-day event, starting Monday, September 22, is “Patients: Hope, Guide, Heal,” focused on quality, safety and patient-centered care.
Dr. Thomas Pisansky, professor of radiation oncology at the Mayo Clinic, outlines the study results.
WE DID A VERY LARGE SCALE STUDY THAT INVOLVED OVER FIFTEEN-HUNDRED MEN AND HALF OF THE MEN GOT A MORE LENGHTY COURSE OF HORMONAL TREATMENT WITH RADIATION THERAPY FOR PROSTATE CANCER AND THE OTHER HALF A MORE ABBREVIATED, A SHORTEND LESSER AMOUNT OF THE HORMONAL THERAPY, AND WHAT WE FOUND IS THAT MEN IN BOTH TREATMENTS DID EQUALLY WELL, BUT THE MEN WHO RECEIVED THE LESSER AMOUNT OF HORMONAL THERAPY HAVE FEWER SIDE EFFECTS. SO THE RESULTS ARE THAT, LESS ACTUALLY IS AS GOOD AS MORE.
For more information, visit www.astro.org.